CloneID: Antibody 80
Antigen Long Description: The original mouse antibody PMA204 was generated by immunizing mice with recombinant human IL-12 as an immunogen. This antibody is the humanized version of the murine antibody PMA204 generated by grafting CDRs of the mouse antibody onto human framework regions. The antibody was further engineered by introducing backmutations and 3 point mutations in the heavy chain and using a combination approach to get the optimized variant.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P29460
Specificity Statement: This antibody specifically binds an epitope between amino acid residues 253 and 286 of the common subunit p40 of the human IL-12 and IL-23. IL-12Rβ1 binding to IL-12 and IL-23 is mediated via the common p40 subunit. IL-12 is a cytokine secreted by activated inflammatory cells (monocytes, macrophages, neutrophils, microglia, dendritic cells). IL-12 can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC. It associated with IL23A to form the IL-23 interleukin, which is a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 is secreted by activated human macrophages as well as dendritic cells. IL-23 predominantly acts on memory T-cells and has been postulated to promote autoimmune disease through the regulation of IL-17A and IL-17F.
Application Notes (Clone): This antibody neutralized the binding of IL-12 to IL-12Rβ2 and IL-23 to IL-23R but did not inhibit the binding of IL-12 or IL-23 or IL-12p40 or IL-12p80 to IL-12Rβ1. The human IgG version of this antibody binds IL-12 and IL-23 with a binding affinity of Kd= 292 pM and Kd= 280 pM respectively. This antibody was reported to inhibit IL-12 induced IFN-gamma release by NK-92 cells and human PBMCs. This antibody can also inhibit IL-23 induced IL-17 secretion by murine splenocytes. The therapeutic efficacy of this antibody was studied in the skin inflammation mouse model. This antibody was reported to significantly decrease epidermal thickness and reduced erythema and induration caused by IL-23. This antibody is capable of detecting recombinant IL-23 and native IL-23 produced by SAC stimulated PBMCs in an ELISA. This antibody showed reduced binding to IL-23 mutants D265A and R266A in an ELISA (US8563697).
Deutsch
English
